Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease

Neurological Research

Volumn 34, Issue 6, 2012, Pages 601-610

  Kurata, Tomoko ^a   Miyazaki, Kazunori ^a   Kozuki, Miki ^a   Morimoto, Nobutoshi ^a   Ohta, Yasuyuki ^a   Ikeda, Yoshio ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Atorvastatin; Inflammation; Pitavastatin; Transgenic mouse

Indexed keywords

ADAPTOR PROTEIN; AMYLOID PRECURSOR PROTEIN; ATORVASTATIN; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PITAVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN NERVE CELL; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; FEMALE; HIGH RISK PATIENT; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PLEIOTROPY; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; PYRROLES; QUINOLINES;

EID: 84864089648     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000054     Document Type: Article

References (51)

1. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
2. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid b protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372-81.
3. Kurata T, Kawarabayashi T, Murakami T, Miyazaki K, Morimoto N, Ohta Y, et al. Enhanced accumulation of phosphorylated a-synuclein in double transgenic mice expressing mutant b-amyloid precursor protein and presenilin-1. J Neurosci Res. 2007;85:2246-52.
4. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-b protein assembly in the brain impairs memory. Nature. 2006;440:352-7.
5. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR. Induction of Alzheimer-like b-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88-94.
6. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321-31.
7. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease b-amyloid peptides Ab 42 and Ab 40 in vitro and in vivo. Proc Natl Acad Sci USA. 2001;98:5856-61.
8. Wolozin B. A fluid connection: cholesterol and Ab. Proc Natl Acad Sci USA. 2001;98:5371-73.
9. Shie F, Jin L, Cook DG, Leverenz JB, LeBoeuf RC. Diet-induced hypercholesterolemia enhances brain Ab accumulation in transgenic mice. Neuroreport. 2002;13:455-9.
10. George AJ, Holsinger RMD, McLean CA, Laughton KM, Beyreuther K, Evin G, et al. APP intracellular domain is increased and soluble Ab is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis. 2004;16:124-32.
11. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, et al. A cholesterol-lowering drug reduces b-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890-9.
12. Petanceska SS, DeRosa S, Olm V. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci. 2002;19:155-61.
13. Tong XK, Nicolakakis N, Fernandes P, Ongali B, Brouillette J, Quirion R, et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-b, inflammation and oxidative stress in aged APP mice. Neurobiol Dis. 2009;35:406-14.
14. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res. 1994;11:305-11.
15. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
16. Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging. 2002;6:324-31.
17. Tanaka N, Katayama Y, Katsumata T, Otori T, Nishiyama Y. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flox in stroke-prone spontaneously hypertensive rats. Brain Res. 2007;169:125-32.
18. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs. 2001;61:1835-81.
19. Cibickova L, Hyspler R, Micuda S, Cibicek N, Zivna H, Jun D, et al. The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid b and cholesterol synthesis in rat brain. Steroids. 2009;74:13-9.
20. Kajinami K, Mabuchi H, Saito Y. NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs. 2000;9:2653-61.
21. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis. 1999;146:259-70.
22. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59:239-52.
23. Masana L. Pitavastatin-from clinical trials to clinical practice. Atheroscler Suppl. 2010;11:15-22.
24. Okamura N, Suemoto T, Shimadzu H, Suzuki M, Shiomitsu T, Akatsu H, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004;10:2535-41.
25. Suzuki H, Kobayashi H, Sato F, Yonemitsu Y, Nakashima Y, Sueishi K. Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb. 2003;10:108-15.
26. Chauhan NB, Siegel GJ, Feinstein DL. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res. 2004;29:1897-911.
27. Li L, Cao D, Kim H, Lester R, Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol. 2006;60:729-39.
28. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-31.
29. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-43.
30. Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis. 2008;13:187-97.
31. Sparks DL, Connor DJ, Sabbagh MN, Peterson RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: result of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. 2006. Acta Neurol Scand. 2006;114(Suppl 185):3-7.
32. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;28:878-85.
33. Nachtigal P, Jamborova G, Pospisilova N, Pospechova K, Solichova D, Zdansky P, et al. Atorvastatin has distinct effects on endothelial markers in different mouse models of athero-sclerosis. J Pharm Pharm Sci. 2006;9:222-30.
34. Cordle A, Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate b-amyloid-induced microglial inflammatory responses. J Neurosci. 2005;25:299-307.
35. Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist. 2007;13:208-13.
36. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956-64.
37. Kurata T, Miyazaki K, Kozuki M, Panin VL, Morimoto N, Ohta Y, et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 2011;1371:161-70.
38. Akiyama H, McGeer PL. Brain microglia constitutively express b-2 integrins. J Neuroimmunol. 1990;30:81-93.
39. Masliah E, Mallory M, Hansen L, Alford M, Albright T, Terry R, et al. Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease. Acta Neuropathol. 1991;83:12-20.
40. Peress NS, Fleit HB, Perillo E, Kuljis R, Pezzullo C. Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease. J Neuroimmunol. 1993;48:71-9.
41. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
42. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of b-amyloid-stimulated proinflammatory responses and neuro-toxicity by PPARgamma agonists. J Neurosci. 2000;20:558-67.
43. Combs CK, Karlo JC, Kao SC, Landreth GE. β-Amyloid stimulation of microglia and monocytes results in TNF a-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci. 2001;21:1179-88.
44. Yates SL, Burgess LH, Kocsis-Angle J, Antal JM, Dority MD, Embury PB, et al. Amyloid b and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J Neurochem. 2000;74:1017-25.
45. Blednov YA, Bergeson SE, Walker D, Ferreira VM, Kuziel WA, Harris RA. Perturbation of chemokine networks by gene deletion alters the reinforcing actions of ethanol. Behav Brain Res. 2005;165:110-25.
46. McManus CM, Liu JS, Hahn MT, Hua LL, Brosnan CF, Berman JW, et al. Differential induction of chemokines in human microglia by type I and II interferons. Glia. 2000;29:273-80.
47. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410:988-94.
48. Little AR, Benkovic SA, Miller DB, O'Callaghan JP. Chemically induced neuronal damage and gliosis: enhanced expression of the proinflammatory chemokine, monocyte chemoattractant protein (MCP)-1, without a corresponding increase in proinflammatory cytokines. Neuroscience. 2001;115:307-20,
49. Mahad DJ, Ransohoff RM. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol. 2003;15:23-32.
50. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxi-city: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57-69.
51. Ohsawa K, Imai Y, Sasaki Y, Kohsaka S. 2004. Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem. 2004;88:844-56.